Clinical trial
Safety and Immune Response to a Multi-component Immune Based Therapy…
NCT00423254 · Mannkind Corporation, Industry · Completed
Key facts
| NCT number | NCT00423254 |
|---|---|
| Title | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
| Official title | A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies |
| Lead sponsor | Mannkind Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma and 14 more |
| Intervention type | Biological |
| Interventions | PSMA/PRAME |
| Enrollment | 12 |
| Start date | Feb 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Jan 18, 2007 |
| Last update posted | Aug 3, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: